By Anupriya Patel
India has firmly established itself as the “pharmacy of the world,” and in line with the vision of Narendra Modi for a Viksit Bharat, the country is now transitioning from being a global supplier of generic medicines to an innovation-driven pharmaceutical powerhouse. The government’s policy focus remains clear—ensuring affordable, high-quality medicines for every citizen while simultaneously strengthening research and development to enhance India’s global competitiveness.
From Generics to Global Innovation Leadership
India’s pharmaceutical success has been built on strong manufacturing capabilities, cost efficiency, and high-quality standards. Currently, the country supplies nearly 20 percent of the world’s generic medicines and about 60 percent of global vaccines, playing a critical role in global health security. Building on this foundation, the government has set an ambitious target to transform India into a global hub for high-value, innovation-led biopharmaceuticals and advanced therapeutics over the next decade.
A key step in this direction is the ₹10,000 crore ‘Biopharma Shakti’ initiative announced in the Union Budget. This program is designed to accelerate scientific research, foster innovation-led industries, and support the development of next-generation medicines. With the pharmaceutical industry currently valued at around $50 billion and projected to reach $130 billion by 2030, the sector represents not just economic growth, but a roadmap for a brighter future for millions of young Indians.
Employment Engine for the Future
The pharmaceutical sector already provides direct and indirect employment to over three million people. By 2030, an additional 2 to 2.5 million jobs are expected to be created across healthcare and pharma. Emerging fields such as biopharma, medical technology, and clinical research are opening new avenues, offering diverse career opportunities for the country’s youth.
However, the nature of work is evolving rapidly. It is estimated that nearly 30–35 percent of the pharma workforce will require reskilling by 2030. Areas such as data analytics, digital health, regulatory affairs, and advanced research are expected to drive demand for highly skilled professionals. Recognising this shift, the government is focusing on bridging the skill gap and ensuring that Indian youth receive world-class training in clinical research and R&D.
Strengthening Education and Research Ecosystems
A robust academic framework is essential to sustain this growth. In a major push, the government has announced the establishment of three new National Institute of Pharmaceutical Education and Research (NIPER) institutions, along with the upgradation of seven existing ones. These institutes are being transformed into centres of excellence, each specialising in critical areas of pharmaceutical research.
Focused research hubs have been set up across the country—ranging from antiviral and antibacterial drug development in Mohali to medical devices in Ahmedabad, bulk drugs in Hyderabad, sustainable manufacturing in Kolkata, novel drug delivery systems in Raebareli, phytopharmaceuticals in Guwahati, and biological therapeutics in Hajipur. These institutions are evolving beyond traditional academic roles to become innovation centres where students work on real-world industry challenges.
This transformation aims to produce not just job seekers, but job creators—entrepreneurs and innovators capable of driving the next phase of India’s pharmaceutical growth.
Bridging Industry and Academia
Reducing the gap between education and industry remains a top priority. Aligning academic curricula with industry needs is crucial to fully leverage India’s demographic dividend. In this direction, over 356 Memorandums of Understanding (MoUs) have been signed between NIPER institutions and industry stakeholders.
Skill development initiatives are also enabling students to directly engage with companies, enhancing their employability and practical exposure. These collaborations are expected to strengthen India’s position as a global innovation hub while ensuring that young professionals are industry-ready.
A Mission Beyond Growth
The growth of the pharmaceutical sector is not merely an economic objective—it is a mission to empower India’s youth. A knowledge-based economy rests on the strength of its scientists, researchers, and skilled professionals. The expansion of NIPER and strategic policy interventions reflect a commitment to building an ecosystem where talent and hard work can translate into global impact.
As India enters what can be described as a golden era for its pharmaceutical industry, the opportunities for young innovators and professionals are immense. This transformation is laying a strong foundation for achieving the vision of Viksit Bharat @2047, positioning India not only as a leader in healthcare but also as a global centre of innovation and excellence.
